-
BTLA: A Key Player in Immune Regulation and Cancer Therapy(Post)
Introduction to BTLA in Immune Regulation B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that plays a critical role in regulating immune responses by suppressing T
Targeting CD200: Unlocking Immune Suppression in Tumors(Post)Immune evasion is one of the hallmarks of cancer, where tumor cells employ various strategies to suppress immune responses and prevent destruction by the body’s defense systems. CD200, a
TNFR2: Taming Regulatory T Cells to Enhance Anti-Tumor Immunity(Post)In recent years, cancer immunotherapy has become a powerful tool for treating various malignancies. One promising approach involves targeting the tumor microenvironment, particularly regu
Narsoplimab: Targeting MASP-2 to Advance Therapies in Immune-Mediated Disorders(Post)Quick Facts About NarsoplimabWhat is Narsoplimab?Narsoplimab is a human monoclonal antibody that targets MASP-2, a key enzyme in the lectin pathway of the complement system.What is the m
CD25 and Tregs: Understanding the Role of Regulatory T Cells in Tumor Immunity(Post)Regulatory T cells (Tregs) play a crucial role in maintaining immune balance by suppressing excessive immune responses that could lead to tissue damage. However, in the context of cancer,
The Rise of Cancer Neuroscience: How Neural Circuits Drive Tumor Progression(Post)For decades, we viewed cancer as a rogue army of cells, a biological glitch driven solely by genetic mutations and metabolic greed. We imagined tumors as isolated fortresses, growing in a vacuum of t
Tesnatilimab: Unveiling the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About TesnatilimabWhat is Tesnatilimab?Tesnatilimab is an anti-CD47 monoclonal antibody designed to block the "don’t eat me" signal used by cancer cells to evade immune respo
OX40 Agonists: Revitalizing the Immune Response in Cancer(Post)Cancer immunotherapy has revolutionized treatment options, offering strategies to harness the immune system to target and destroy tumors. One emerging area of interest is the use of OX40
Emapalumab: Unlocking the Potential of Targeting IFN-γ in HLH Treatment(Post)Quick Facts About EmapalumabWhat is Emapalumab?Emapalumab is a fully human monoclonal antibody that neutralizes interferon-gamma (IFN-γ). It is the first FDA-approved therapy for primary
LAG-3: Revitalizing T Cells in Exhaustion for Combination Therapies(Post)Lymphocyte Activation Gene-3 (LAG-3) is an immune checkpoint receptor that plays a critical role in regulating T cell function. In recent years, LAG-3 has emerged as a potential target fo
Monalizumab: A Breakthrough in Cancer Immunotherapy Targeting NKG2A(Post)Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking
Relatlimab: Unlocking the Potential of LAG-3 Inhibition in Cancer Research(Post)Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio
The Neural Shield: How Cancer-Induced Nerve Injury Drives Immunotherapy Resistance(Post)For years, our understanding of cancer focused primarily on the tumor cells themselves and the immune system's response. However, a groundbreaking wave of research is revealing a startling truth: ner
CD73: Combating Tumor Immunosuppression by Targeting Adenosine(Post)Introduction to CD73 and Tumor Immunosuppression CD73, also known as ecto-5'-nucleotidase, is an enzyme found on the surface of various cells, including tumor cells and immune cells. It p
Plonmarlimab: Advancing Anti-GM-CSF Therapy in Inflammatory Diseases(Post)Quick Facts About PlonmarlimabWhat is Plonmarlimab?Plonmarlimab is a monoclonal antibody targeting GM-CSF, a cytokine involved in inflammation and immune responses.How does Plonmarlimab
Immunoglobulin Antibodies: Types, Structure & Clinical Uses(Post)Immunoglobulin antibodies stand at the forefront of the immune defense system, offering a sophisticated mechanism for recognizing and neutralizing a vast array of pathogens, including bacteria, v
Cobolimab: Unveiling TIM-3’s Role in Cancer Immunotherapy(Post)Quick Facts About CobolimabWhat is Cobolimab?Cobolimab is a monoclonal antibody that targets TIM-3, a checkpoint protein involved in immune regulation, especially in cancer and autoimmun
Mitophagy: The Cell's Cleanup Crew for Healthy Living(Post)Mitophagy, a term derived from the fusion of "mitochondria" and "autophagy," represents a vital cellular process responsible for the targeted degradation and recycling of dysfunctional mitochon
B7-H4: A New Frontier in Immune Checkpoint Inhibition(Post)The recent advances in cancer immunotherapy have brought new opportunities to harness the body’s immune system against tumors. Among these advancements is the targeting of immune checkpoi
Myeloid Cell Networks in Cancer Immunotherapy(Post)Understanding Myeloid Cell Networks in Cancer ImmunotherapyImmunotherapy has revolutionized cancer treatment, yet its effectiveness in re-establishing original immune responses post-therapy remains li
Abituzumab: Understanding Its Role in Cancer and Fibrosis Research(Post)Quick Facts About AbituzumabWhat is Abituzumab?Abituzumab is a monoclonal antibody that targets αv-integrins, playing a role in cancer treatment and fibrotic diseases.What is the mechani
Bone Resorption Explained: Process, Markers, and Clinical Insights(Post)Bone Biology · BiomarkersBone Resorption: Process, Markers & Clinical SignificanceBone resorption is the process by which osteoclasts break down bone tissue and release its stored minerals into the bl
GeniePlex Featured Publications(Page) Programmable Synthetic Hybrid Receptors (Hybrid-Rs): The Next Generation of Precision Immunotherapy(Post)Imagine a world where cancer treatment is no longer a blunt instrument but a precision-guided surgical strike, executed by the body's own immune system. For years, we have dreamed of 'smart' cells th
Volagidemab: A Breakthrough in GLP-1 Receptor Agonists for Metabolic Disorders(Post)Quick Facts About VolagidemabWhat is Volagidemab?Volagidemab is a glucagon-like peptide-1 (GLP-1) receptor antagonist designed to regulate glucose metabolism and energy homeostasis.How D
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
Siltuximab: Exploring IL-6 Inhibition in Castleman’s Disease and Research(Post)Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the m
Genieplex Multiplex Citations(Page) T-cell receptor (TCR) signalling(Page) cGAS-STING cytosolic DNA sensing(Page) CIDE: The New Bioinformatics Engine Unmasking Secreted Proteins for Precision Immunotherapy(Post)For decades, the battle against cancer has focused on the cellular 'soldiers' and the genetic 'blueprints' within them. Yet, a vast, invisible world of communication exists between these cells—a secr
Eldelumab: Unlocking the Potential of Anti-TNFSF14 in Inflammatory Diseases(Post)Quick Facts About EldelumabWhat is Eldelumab?Eldelumab is a monoclonal antibody targeting TNFSF14 (LIGHT), a key regulator in immune system signaling, with potential applications in infl
EGFR Pathway and YAP in Non-Small Cell Lung Cancer(Post)Understanding the EGFR Pathway and YAP in Non-Small Cell Lung CancerThe epidermal growth factor receptor (EGFR) pathway plays a pivotal role in the development and progression of non-small cell lung c
The Brain's Sentinels: How Microglia Shape Neuroinflammation in Disease(Post)The Brain's Sentinels: How Microglia Shape Neuroinflammation in Disease In the intricate landscape of the human brain, a silent, ever-watchful guardian stands ready to defend against injury and invas
MHC Class I vs Class II: Key Differences & Functions [Guide](Post)Immunology Guide MHC Class I vs Class II: Key Differences & Functions [Guide] Major Histocompatibility Complex molecules present antigens to T
B7-H3: A Promising New Target in Tumor Immunotherapy(Post)B7-H3, also known as CD276, is a member of the B7 family of immune checkpoint molecules that has emerged as a compelling target in tumor immunotherapy. Initially recognized for its role i
Tiragolumab: Unlocking New Horizons in Cancer Immunotherapy(Post)Quick Facts About TiragolumabWhat is Tiragolumab?Tiragolumab is an anti-TIGIT monoclonal antibody developed to enhance immune responses against cancer cells. It is currently under invest
Rituximab: Mechanism, Applications, and Research Potential(Post)Quick Facts About RituximabWhat is Rituximab?Rituximab is a monoclonal antibody targeting CD20, a protein found on the surface of B cells. It plays a crucial role in treating autoimmune
Indusatumab: Advancing Anti-CD47 Cancer Research with Biosimilar Innovations(Post)Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does
Vibostolimab: Mechanism, Clinical Applications, and Research Potential in Oncology(Post)Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity
Lirilumab: Unlocking the Potential of Anti-KIR Therapy in Cancer Research(Post)Quick Facts About LirilumabWhat is Lirilumab?Lirilumab is an anti-KIR monoclonal antibody designed to enhance natural killer (NK) cell activity by blocking killer-cell immunoglobulin-lik
Polatuzumab: Redefining Targeted Therapies in B-Cell Lymphoma(Post)What You Need to Know About PolatuzumabWhat is Polatuzumab??Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, a component of the B-cell receptor, used primarily in B-cel
Labeling Non-Antibody Proteins and Small Molecules: An Advanced Guide(Post)In the evolving landscape of biochemical research and diagnostic assay development, the ability to label non-antibody proteins and small molecules with high precision has become indispensable. Thi
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
Cabiralizumab: Unlocking the Potential of Anti-CSF1R Therapy(Post)What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c
SIRPα Inhibition: Clearing Tumors by Promoting Phagocytosis(Post)Cancer cells are adept at avoiding destruction by the immune system, often exploiting specific pathways to escape detection and elimination. One of these key mechanisms involves the SIRPα
Glenzocimab: A Novel Antiplatelet Therapy for Stroke Prevention(Post)Quick Facts About GlenzocimabWhat is Glenzocimab?Glenzocimab is an innovative monoclonal antibody designed to reduce the risk of ischemic stroke by selectively targeting platelet glycopr
Molecular Biology(Page)Molecular Biology Tools, PCR & Cloning Kits | Assay Genie
Cell Viability, Cytotoxicity & Proliferation Assays(Page)Cell Viability, Cytotoxicity & Proliferation Assay Kits | Assay Genie
Elotuzumab: Revolutionizing Multiple Myeloma Treatment and Research Applications(Post)Quick Facts About ElotuzumabWhat is Elotuzumab?Elotuzumab is a monoclonal antibody designed to enhance the immune system's ability to detect and destroy multiple myeloma cells. It target
Enokizumab: Exploring Its Mechanism, Clinical Applications, and Biosimilar Advancements(Post)Quick Facts About EnokizumabWhat is Enokizumab?Enokizumab is a monoclonal antibody designed to target interleukin-9 (IL-9), a cytokine involved in inflammatory responses. It has been stu
IgG1 Plasma Cells: The Emerging Biomarker for Predicting Cancer Immunotherapy Success(Post)In the relentless fight against cancer, immunotherapy has emerged as a beacon of hope, harnessing the body's own defenses to combat malignant cells. Yet, predicting which patients will respond to the
Unlocking the Fortress: CAR-T Cell Therapy's Next Frontier in Solid Tumors(Post)For years, the success of CAR-T cell therapy has been a beacon of hope in the fight against blood cancers, offering remarkable remissions where other treatments have failed. Yet, solid tumors—the form
Turning Tumors Against Themselves: In Vivo Reprogramming of Cancer Cells into Dendritic Sentinels(Post)Imagine a future where cancer cells, once masters of disguise, are forced to reveal themselves and even train the body's immune system to fight back. This isn't science fiction; it's the groundbreaki
CD4+ T-helper cell differentiation(Page) Regulatory T-cell (Treg) suppression & the IL-2 axis(Page) Adaptive immune system molecules(Page) Narnatumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About NarnatumabWhat is Narnatumab?Narnatumab is a monoclonal antibody targeting CD47, a key immune checkpoint that helps cancer cells evade destruction by the immune system.
Milatuzumab: Unveiling Its Role in Cancer Immunotherapy and Research(Post)What You Need to Know About MilatuzumabWhat is Milatuzumab?Milatuzumab is a humanized monoclonal antibody targeting CD74, a molecule involved in antigen presentation and cell signaling.W